450 related articles for article (PubMed ID: 15542195)
21. [Protective antibody response to recombinant fragments of Plasmodium falciparum apical membrane antigen 1].
Li X; Xue CF; Liu ZX; Wang XF; Ding J; Lei JC; Zhen RF
Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2003; 21(2):80-3. PubMed ID: 12884614
[TBL] [Abstract][Full Text] [Related]
22. Functional analysis of Plasmodium falciparum apical membrane antigen 1 utilizing interspecies domains.
Healer J; Triglia T; Hodder AN; Gemmill AW; Cowman AF
Infect Immun; 2005 Apr; 73(4):2444-51. PubMed ID: 15784590
[TBL] [Abstract][Full Text] [Related]
23. Lack of allele-specific efficacy of a bivalent AMA1 malaria vaccine.
Ouattara A; Mu J; Takala-Harrison S; Saye R; Sagara I; Dicko A; Niangaly A; Duan J; Ellis RD; Miller LH; Su XZ; Plowe CV; Doumbo OK
Malar J; 2010 Jun; 9():175. PubMed ID: 20565971
[TBL] [Abstract][Full Text] [Related]
24. Defining the antigenic diversity of Plasmodium falciparum apical membrane antigen 1 and the requirements for a multi-allele vaccine against malaria.
Drew DR; Hodder AN; Wilson DW; Foley M; Mueller I; Siba PM; Dent AE; Cowman AF; Beeson JG
PLoS One; 2012; 7(12):e51023. PubMed ID: 23227229
[TBL] [Abstract][Full Text] [Related]
25. Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research.
Polhemus ME; Magill AJ; Cummings JF; Kester KE; Ockenhouse CF; Lanar DE; Dutta S; Barbosa A; Soisson L; Diggs CL; Robinson SA; Haynes JD; Stewart VA; Ware LA; Brando C; Krzych U; Bowden RA; Cohen JD; Dubois MC; Ofori-Anyinam O; De-Kock E; Ballou WR; Heppner DG
Vaccine; 2007 May; 25(21):4203-12. PubMed ID: 17442466
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of two long synthetic merozoite surface protein 2 peptides as malaria vaccine candidates.
Flueck C; Frank G; Smith T; Jafarshad A; Nebie I; Sirima SB; Olugbile S; Alonso P; Tanner M; Druilhe P; Felger I; Corradin G
Vaccine; 2009 May; 27(20):2653-61. PubMed ID: 19428875
[TBL] [Abstract][Full Text] [Related]
27. Specificity of the protective antibody response to apical membrane antigen 1.
Hodder AN; Crewther PE; Anders RF
Infect Immun; 2001 May; 69(5):3286-94. PubMed ID: 11292751
[TBL] [Abstract][Full Text] [Related]
28. How specific is the immune response to malaria in adults living in endemic areas?
Mannan BA; Patel K; Malhotra I; Ravindran B; Sharma S
J Vector Borne Dis; 2003; 40(3-4):84-91. PubMed ID: 15119077
[TBL] [Abstract][Full Text] [Related]
29. Do antibody responses to malaria vaccine candidates influenced by the level of malaria transmission protect from malaria?
Nebie I; Tiono AB; Diallo DA; Samandoulougou S; Diarra A; Konate AT; Cuzin-Ouattara N; Theisen M; Corradin G; Cousens S; Ouattara AS; Ilboudo-Sanogo E; Sirima BS
Trop Med Int Health; 2008 Feb; 13(2):229-37. PubMed ID: 18304269
[TBL] [Abstract][Full Text] [Related]
30. Antibody levels to multiple malaria vaccine candidate antigens in relation to clinical malaria episodes in children in the Kasena-Nankana district of Northern Ghana.
Dodoo D; Atuguba F; Bosomprah S; Ansah NA; Ansah P; Lamptey H; Egyir B; Oduro AR; Gyan B; Hodgson A; Koram KA
Malar J; 2011 May; 10():108. PubMed ID: 21529376
[TBL] [Abstract][Full Text] [Related]
31. Longitudinal analyses of immune responses to Plasmodium falciparum derived peptides corresponding to novel blood stage antigens in coastal Kenya.
Agak GW; Bejon P; Fegan G; Gicheru N; Villard V; Kajava AV; Marsh K; Corradin G
Vaccine; 2008 Apr; 26(16):1963-71. PubMed ID: 18342997
[TBL] [Abstract][Full Text] [Related]
32. Overcoming allelic specificity by immunization with five allelic forms of Plasmodium falciparum apical membrane antigen 1.
Miura K; Herrera R; Diouf A; Zhou H; Mu J; Hu Z; MacDonald NJ; Reiter K; Nguyen V; Shimp RL; Singh K; Narum DL; Long CA; Miller LH
Infect Immun; 2013 May; 81(5):1491-501. PubMed ID: 23429537
[TBL] [Abstract][Full Text] [Related]
33. Variations in the quality of malaria-specific antibodies with transmission intensity in a seasonal malaria transmission area of Northern Ghana.
Kusi KA; Manu EA; Manful Gwira T; Kyei-Baafour E; Dickson EK; Amponsah JA; Remarque EJ; Faber BW; Kocken CHM; Dodoo D; Gyan BA; Awandare GA; Atuguba F; Oduro AR; Koram KA
PLoS One; 2017; 12(9):e0185303. PubMed ID: 28945794
[TBL] [Abstract][Full Text] [Related]
34. Human adenovirus 5-vectored Plasmodium falciparum NMRC-M3V-Ad-PfCA vaccine encoding CSP and AMA1 is safe, well-tolerated and immunogenic but does not protect against controlled human malaria infection.
Tamminga C; Sedegah M; Maiolatesi S; Fedders C; Reyes S; Reyes A; Vasquez C; Alcorta Y; Chuang I; Spring M; Kavanaugh M; Ganeshan H; Huang J; Belmonte M; Abot E; Belmonte A; Banania J; Farooq F; Murphy J; Komisar J; Richie NO; Bennett J; Limbach K; Patterson NB; Bruder JT; Shi M; Miller E; Dutta S; Diggs C; Soisson LA; Hollingdale MR; Epstein JE; Richie TL
Hum Vaccin Immunother; 2013 Oct; 9(10):2165-77. PubMed ID: 23899517
[TBL] [Abstract][Full Text] [Related]
35. High affinity antibodies to Plasmodium falciparum merozoite antigens are associated with protection from malaria.
Reddy SB; Anders RF; Beeson JG; Färnert A; Kironde F; Berenzon SK; Wahlgren M; Linse S; Persson KE
PLoS One; 2012; 7(2):e32242. PubMed ID: 22363818
[TBL] [Abstract][Full Text] [Related]
36. Antibodies to a Plasmodium falciparum blood-stage antigen as a tool for predicting the protection levels of two malaria-exposed populations.
Astagneau P; Roberts JM; Steketee RW; Wirima JJ; Lepers JP; Deloron P
Am J Trop Med Hyg; 1995 Jul; 53(1):23-8. PubMed ID: 7542843
[TBL] [Abstract][Full Text] [Related]
37. Strain-specific Plasmodium falciparum growth inhibition among Malian children immunized with a blood-stage malaria vaccine.
Laurens MB; Kouriba B; Bergmann-Leitner E; Angov E; Coulibaly D; Diarra I; Daou M; Niangaly A; Blackwelder WC; Wu Y; Cohen J; Ballou WR; Vekemans J; Lanar DE; Dutta S; Diggs C; Soisson L; Heppner DG; Doumbo OK; Plowe CV; Thera MA
PLoS One; 2017; 12(3):e0173294. PubMed ID: 28282396
[TBL] [Abstract][Full Text] [Related]
38. Overcoming antigenic diversity by enhancing the immunogenicity of conserved epitopes on the malaria vaccine candidate apical membrane antigen-1.
Dutta S; Dlugosz LS; Drew DR; Ge X; Ababacar D; Rovira YI; Moch JK; Shi M; Long CA; Foley M; Beeson JG; Anders RF; Miura K; Haynes JD; Batchelor AH
PLoS Pathog; 2013; 9(12):e1003840. PubMed ID: 24385910
[TBL] [Abstract][Full Text] [Related]
39. Age-dependent association between IgG2 and IgG3 subclasses to Pf332-C231 antigen and protection from malaria, and induction of protective antibodies by sub-patent malaria infections, in Daraweesh.
Giha HA; Nasr A; Iriemenam NC; Balogun HA; Arnot D; Theander TG; Troye-Blomberg M; Berzins K; ElGhazali G
Vaccine; 2010 Feb; 28(7):1732-9. PubMed ID: 20036751
[TBL] [Abstract][Full Text] [Related]
40. Natural antibody response to Plasmodium falciparum Exp-1, MSP-3 and GLURP long synthetic peptides and association with protection.
Meraldi V; Nebié I; Tiono AB; Diallo D; Sanogo E; Theisen M; Druilhe P; Corradin G; Moret R; Sirima BS
Parasite Immunol; 2004; 26(6-7):265-72. PubMed ID: 15541030
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
